BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 11861387)

  • 21. In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter?
    Modesitt SC; Parsons SJ
    Gynecol Oncol; 2010 Nov; 119(2):351-7. PubMed ID: 20673975
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effects of PI3K/Akt/NF-κB signal pathway on FSH facilitation on cell proliferation and invasion by human epithelial ovarian cancer].
    Xu CL; Lu XL; Yan XN; Wang HL; Chen SQ
    Zhonghua Fu Chan Ke Za Zhi; 2012 Feb; 47(2):134-8. PubMed ID: 22455747
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non-small cell lung cancer in vitro and in vivo.
    Denlinger CE; Rundall BK; Jones DR
    J Thorac Cardiovasc Surg; 2005 Nov; 130(5):1422-9. PubMed ID: 16256798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells.
    Zhou C; Qiu L; Sun Y; Healey S; Wanebo H; Kouttab N; Di W; Yan B; Wan Y
    Int J Oncol; 2006 Jul; 29(1):269-78. PubMed ID: 16773209
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PI3K/Akt inhibitor LY294002 potentiates homoharringtonine antimyeloma activity in myeloma cells adhered to stromal cells and in SCID mouse xenograft.
    Chen P; Wen X; Wang B; Hou D; Zou H; Yuan Q; Yang H; Xie J; Huang H
    Ann Hematol; 2018 May; 97(5):865-875. PubMed ID: 29450644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combinatorial therapy with adenoviral-mediated PTEN and a PI3K inhibitor suppresses malignant glioma cell growth in vitro and in vivo by regulating the PI3K/AKT signaling pathway.
    Nan Y; Guo L; Song Y; Wang L; Yu K; Huang Q; Zhong Y
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1477-1487. PubMed ID: 28401302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phosphoinositide-3-kinase inhibition enhances radiosensitization of cervical cancer in vivo.
    Liu Y; Cui B; Qiao Y; Zhang Y; Tian Y; Jiang J; Ma D; Kong B
    Int J Gynecol Cancer; 2011 Jan; 21(1):100-5. PubMed ID: 21330835
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
    Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
    Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines.
    Lee CM; Fuhrman CB; Planelles V; Peltier MR; Gaffney DK; Soisson AP; Dodson MK; Tolley HD; Green CL; Zempolich KA
    Clin Cancer Res; 2006 Jan; 12(1):250-6. PubMed ID: 16397049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergism of PI3K/Akt inhibition and Fas activation on colon cancer cell death.
    Zhu L; Derijard B; Chakrabandhu K; Wang BS; Chen HZ; Hueber AO
    Cancer Lett; 2014 Nov; 354(2):355-64. PubMed ID: 25199763
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
    Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
    Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
    Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
    Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dual blockade of phosphatidylinositol 3'-kinase and mitogen-activated protein kinase pathways overcomes paclitaxel-resistance in colorectal cancer.
    Xu R; Nakano K; Iwasaki H; Kumagai M; Wakabayashi R; Yamasaki A; Suzuki H; Mibu R; Onishi H; Katano M
    Cancer Lett; 2011 Jul; 306(2):151-60. PubMed ID: 21429662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Simultaneous inhibition of the mitogen-activated protein kinase kinase and phosphatidylinositol 3'-kinase pathways enhances sensitivity to paclitaxel in ovarian carcinoma.
    Kawaguchi W; Itamochi H; Kigawa J; Kanamori Y; Oishi T; Shimada M; Sato S; Shimogai R; Sato S; Terakawa N
    Cancer Sci; 2007 Dec; 98(12):2002-8. PubMed ID: 17900261
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel.
    Mitsuuchi Y; Johnson SW; Selvakumaran M; Williams SJ; Hamilton TC; Testa JR
    Cancer Res; 2000 Oct; 60(19):5390-4. PubMed ID: 11034077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells.
    Lane D; Robert V; Grondin R; Rancourt C; Piché A
    Int J Cancer; 2007 Sep; 121(6):1227-37. PubMed ID: 17534891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer.
    Furuya F; Lu C; Willingham MC; Cheng SY
    Carcinogenesis; 2007 Dec; 28(12):2451-8. PubMed ID: 17660507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of PI3K/Akt pathway inhibition-mediated G1 arrest on chemosensitization in ovarian cancer cells.
    Fekete M; Santiskulvong C; Eng C; Dorigo O
    Anticancer Res; 2012 Feb; 32(2):445-52. PubMed ID: 22287731
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer.
    Cooper AL; Greenberg VL; Lancaster PS; van Nagell JR; Zimmer SG; Modesitt SC
    Gynecol Oncol; 2007 Mar; 104(3):596-601. PubMed ID: 17049973
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon alpha combined with paclitaxel.
    Tedjarati S; Baker CH; Apte S; Huang S; Wolf JK; Killion JJ; Fidler IJ
    Clin Cancer Res; 2002 Jul; 8(7):2413-22. PubMed ID: 12114447
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.